FOLH1 and prostate carcinoma: Among them, few lanthanide-based compounds were able to undergo clinical trials, such as 177Lu-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in radiotherapy against metastatic castration-resistant prostate cancer (in phase II) [14], motexafin gadolinium for photodynamic therapy against brain metastasis (in phase III) or gadofosveset trisodium (based also on GdIII) for imageology of blood vessels (in phase IV) [15].